Triclosan Toothpaste in the Maintenance Phase of Peri-implantitis Treatment.

June 16, 2017 updated by: Belén Retamal-Valdes, University of Guarulhos

Effects of a Toothpaste Containing 0.3% Triclosan in the Maintenance Phase of Peri-implantitis Treatment.

The aim of this study was to evaluate the effects of a dentifrice containing 0.3% triclosan on periodontal and peri-implant parameters in patients, with or without periodontitis, treated for peri-implantitis and that were enrolled in a maintenance phase for two years.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Although dental implants have a high success rate, the prevalence of peri-implantitis has been rising worldwide. Similarly to periodontitis, peri-implantis are complex infections caused by oral pathogens that colonize the oral cavity tissues. Then, several anti-infective treatments have been proposed to treat peri-implantitis. Although an ideal and definitive therapy has not yet been established, one of the most commonly used protocols is the open-flap mechanical decontamination of the implant surfaces. Nonetheless, it has been well established that after the active treatment phase, it is essential that patients enter a maintenance phase, similarly to that followed by patients who have had periodontitis. One of the main risk indicators for peri-implantitis is poor oral hygiene, so the maintenance phase should include strict control of the supra and submucosal biofilms. Several methods, including the use of dental and interdental brushes, are usually recommended for the mechanical control of biofilm accumulated in implant surfaces; however, many patients are not able to effectively remove this biofilm. Thus, the use of a chemical adjunct to traditional mechanical methods during the maintenance phase of peri-implantitis treatment could improve the long term stability of dental implants. Among the several antimicrobial agents used to control biofilm accumulation in the oral cavity, triclosan is one of the most effective. Therefore, the aim of this study was to evaluate the effects of a dentifrice containing 0.3% triclosan on periodontal and peri-implant parameters in patients, with or without periodontitis, treated for peri-implantitis and that were enrolled in a maintenance phase for two years. Subjects presenting at least one implant with peri-implantitis, received surgical anti-infective therapy consisting of mechanical debridement of the implant surfaces with scalers and sodium bicarbonate jet were entered into the study. Sixty days later (baseline), subjects were randomized into two groups: (i) brushing with a toothpaste containing 0.3% triclosan + 1450 ppm fluoride (test) or (ii) brushing with a toothpaste containing 1450 ppm fluoride (control). Subjects received clinical and microbiological monitoring at baseline, 3, 6, 12, 18 and 24 months post-therapy. 102 subjects were enrolled (test, n= 48; control, n=54) in the study. The results for peri-implant parameters showed that the control group had loss of relative clinical attachment level (CAL) over the course of the study (p<0.05) while the test group showed stability for this parameter. The difference between groups for CAL change between baseline and 24 months (0.55 mm) was statistically significant (primary outcome variable). The red complex pathogens were only reduced in the test group at 24 months. The periodontal parameters results showed that the test group (n=39) had a greater reduction in the percentage of sites exhibiting bleeding on probing and lower levels of plaque in comparison with the control group (n=49) after 24 months of brushing with the assigned toothpastes (p<0.05). The mean percentage of sites with probing depth ≥ 5mm was reduced over the course of the study only in the test group (p<0.05). The data of the present study showed that a toothpaste containing 0.3% triclosan was more effective than a regular fluoride toothpaste in maintaining peri-implant clinical stability and a more beneficial subgingival microbial profile in subjects with or without a history of periodontitis, that have been treated for peri-implantitis and were enrolled in a regular maintenance program for 2 years. In addition, a toothpaste containing 0.3% triclosan was more effective in maintaining a healthier periodontal environment around natural teeth.

Study Type

Interventional

Enrollment (Actual)

102

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Brazil
    • Santa Catarina
      • Maringa, Santa Catarina, Brazil, 87020-900
        • State University of Maringá
    • São Paulo
      • Guarulhos, São Paulo, Brazil, 07023-070
        • Guarulhos University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • aged between 18-70 years;
  • general good health;
  • minimum of 1 dental implant in function for at least one year with untreated peri-implantitis defined as: probing depth (PD) ≥ 5 mm, bleeding on probing (BOP) or suppuration, radiographic bone loss involving 2 mm from the upper border of the intrabony portion of the implant.

Exclusion Criteria:

  • untreated periodontitis (defined as ≥ 6 sites with PD ≥ 5 mm);
  • periodontal treatment within three months prior to entering the study;
  • inability to perform proper supragingival plaque control (e.g. due to improper prosthesis design or lack of skills);
  • diabetes;
  • pregnancy;
  • nursing;
  • history of allergies to triclosan, fluoride or any other ingredient of oral care products;
  • alcohol or drug abuse;
  • any systemic diseases that could affect post-operative healing;
  • any systemic diseases that required antibiotic premedication for routine dental therapy;
  • long-term use of mouthrinses, anti-inflammatory medications or any other drug that could interfere with the study outcomes within three months prior to entering the study;
  • antibiotics use within six months prior to entering the study;
  • participation in any other clinical study within three months prior to entering the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Test: Triclosan toothpaste

To brush twice a day with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.

Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction.
Procedure: Surgical anti-infective therapy
Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
Other Names:
  • Pre-baseline phase - surgery
Procedure: Periodontal treatment
Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
Other Names:
  • Pre-baseline phase - SRP
Procedure: Oral Hygiene Instruction
Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
Other Names:
  • OHI
Drug: Triclosan toothpaste
Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
Other Names:
  • Triclosan
Procedure: Regular maintenance program
OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
Other Names:
  • Maintenance
PLACEBO_COMPARATOR: Control: Fluoride toothpaste

To brush twice a day with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.

Two months earlier, subjects received Surgical anti-infective therapy for implants with peri-implantitis, periodontal treatment and oral hygiene instruction.
Procedure: Surgical anti-infective therapy
Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
Other Names:
  • Pre-baseline phase - surgery
Procedure: Periodontal treatment
Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
Other Names:
  • Pre-baseline phase - SRP
Procedure: Oral Hygiene Instruction
Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
Other Names:
  • OHI
Procedure: Regular maintenance program
OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
Other Names:
  • Maintenance
Drug: Fluoride toothpaste
Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
Other Names:
  • Fluoride

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical Attachment Level (CAL) at 24 months.
Time Frame: 24 months
Difference between groups for the change in Clinical Attachment Level (CAL) from baseline to 24 months.
24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Probing Depth (PD) ≥ 5 mm.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Number of sites with Probing Depth (PD) ≥ 5 mm, evaluated in all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
PD ≥ 6 mm.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Number of sites with PD ≥ 6 mm, evaluated in all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
PD ≥ 7 mm.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Number of sites with PD ≥ 7 mm, evaluated in all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
Full-mouth PD.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Mean of the PD evaluated in all the periodontal sites from all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
Full-mouth CAL.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Mean of the CAL evaluated in all the periodontal sites from all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
Bleeding on Probing (BOP).
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Percentage of sites with bleeding on probing (BOP), evaluated in all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
Plaque accumulation.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Percentage of sites with plaque accumulation, evaluated in all volunteers.
Baseline, 3, 6, 12, 18, 24 months.
Marginal bleeding.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Percentage of sites with marginal bleeding.
Baseline, 3, 6, 12, 18, 24 months.
Sites gaining CAL ≥ 2mm.
Time Frame: Baseline - 24 months.
Percentage of sites gaining ≥ 2mm of CAL.
Baseline - 24 months.
Sites loosing CAL ≥ 2mm
Time Frame: Baseline - 24 months.
Percentage of sites loosing ≥ 2mm of CAL
Baseline - 24 months.
Radiographic Bone Height
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Mean values of radiographic bone height
Baseline, 3, 6, 12, 18, 24 months.
BOP reduction
Time Frame: Baseline - 24 months.
Reduction in the percentage of sites exhibiting BOP.
Baseline - 24 months.
Adverse effects
Time Frame: 3, 6, 12, 18, 24 months.
Occurrence of nausea and irritability obtained through a questionnaire of adverse effects
3, 6, 12, 18, 24 months.
Proportions of periodontal pathogenic bacterial species.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Proportions of periodontal pathogenic bacterial species in subgingival biofilm samples.
Baseline, 3, 6, 12, 18, 24 months.
Counts of periodontal pathogenic bacterial species.
Time Frame: Baseline, 3, 6, 12, 18, 24 months.
Proportions of periodontal pathogenic bacterial species in subgingival biofilm samples.
Baseline, 3, 6, 12, 18, 24 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Guarulhos

Collaborators

Universidade Estadual de Maringá

Investigators

  • Study Director: Magda Feres, Professor, Guarulhos University
  • Study Chair: Bernal Stewart, Colgate-Palmolive Company

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

June 1, 2010

Primary Completion (ACTUAL)

December 1, 2014

Study Completion (ACTUAL)

June 1, 2017

Study Registration Dates

First Submitted

June 8, 2017

First Submitted That Met QC Criteria

June 16, 2017

First Posted (ACTUAL)

June 19, 2017

Study Record Updates

Last Update Posted (ACTUAL)

June 19, 2017

Last Update Submitted That Met QC Criteria

June 16, 2017

Last Verified

June 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CAAE - 0007.0.132.000-10

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

March 2017

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontal Diseases

Clinical Trials on Surgical anti-infective therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe